Tiny study probes gene link to kidney stones

NCT ID NCT04430426

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study looks at how a specific gene change (AGXT) affects oxalate production in people who have had calcium oxalate kidney stones. Four participants will eat a low-oxalate diet for five days and then receive an intravenous dose of glycolate. Researchers will measure oxalate levels in blood and urine to understand how the gene change influences stone risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glycolate administered intravenously
What this could lead to: If successful, this could help identify people at higher risk for kidney stones and point toward new prevention strategies.
What could go wrong: This is a very small, early study with only 4 participants. It is designed to gather knowledge, not to test a treatment, so direct benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CALCIUM OXALATE KIDNEY STONES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kidney Calculi nephrolithiasis nephrolithiasis, calcium oxalate

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY STONE UROLITHIASIS, CALCIUM OXALATE

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.